ESMO 2026

Connect with Medicover Genetics at ESMO Congress 2026

23-27 October 2026 | IFEMA Madrid, Spain | Booth #1002

Medicover Genetics is pleased to participate in the ESMO Congress 2026, bringing together the global oncology community to explore the latest advances in cancer research, diagnostics and precision medicine.

Find us at booth #1002 to learn how Medicover Genetics combines advanced molecular diagnostics, translational research and clinical genomics expertise to support clinical decision-making across the cancer care continuum.

From molecular evidence to clinical insight

As oncology continues to evolve, access to reliable molecular information is increasingly important for treatment selection, disease monitoring and personalised patient care.

Medicover Genetics collaborates with healthcare professionals and research partners to generate and apply molecular evidence that supports clinical practice. Our comprehensive oncology portfolio spans hereditary cancer testing, tumour profiling, liquid biopsy and molecular residual disease monitoring solutions designed to help clinicians navigate increasingly complex treatment pathways.

Discover our precision oncology solutions

for the assessment of inherited cancer risk and informed patient management.
to identify clinically relevant genomic alterations and potential therapeutic opportunities.
providing evidence-based assessment of therapy-relevant pharmacogenomic markers to support treatment and dosing decisions in line with recognised pharmacogenomic recommendations and guidelines.
enabling non-invasive detection of clinically actionable genomic alterations to support molecular profiling, treatment selection and therapy optimisation when tumour tissue is limited or unavailable.
Minimal residual disease monitoring employing longitudinal ctDNA analysis to detect molecular evidence of residual disease and support disease surveillance over time.

Advancing liquid biopsy research

At ESMO 2026, we will also highlight our ongoing work in liquid biopsy and molecular monitoring. OncoSentia MRD is a tumour-agnostic and plasma-informed ctDNA assay intended for patients diagnosed with unresectable stage II / III NSCLC. The assay has demonstrated the prognostic utility of longitudinal ctDNA assessment, enabling more informed evaluation of disease progression risk alongside established clinical and radiological monitoring approaches.

Let's meet!

Whether your focus is hereditary cancer genetics, tumour molecular profiling, liquid biopsy or emerging approaches in molecular disease monitoring, our scientific and commercial teams look forward to exchanging insights, discussing clinical applications and exploring opportunities for collaboration.

Book a meeting by filling in this contact form.

Your role *

Please select the option that best describes you.

FIRST NAME *

Please enter your first name.

LAST NAME *

Please enter your last name.

PHONE

Providing your phone number is optional and helps us contact you more quickly if needed.

EMAIL ADDRESS *

Please enter a valid email address

Country *

Please provide your country of residence. This information is required to route your request to the appropriate sales representative based on your location.

ORGANISATION / INSTITUTION

Please enter your organisation / institution

MESSAGE / ADDITIONAL NOTES

Please do not enter sensitive health data or special categories of personal data here. If you need to share such information, please use a secure, separate communication channel, such as encrypted email, a protected patient portal or a confidential phone call.

Your data will be used solely for processing your inquiry. For more information on how we handle your personal data and your rights, please refer to our .

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA-accredited, GMP- and ISO9001, 15189 and 13485 certified